GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Cash Flow from Discontinued Operations

Ocumension Therapeutics (HKSE:01477) Cash Flow from Discontinued Operations : HK$0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Ocumension Therapeutics Cash Flow from Discontinued Operations?

Cash flow from discontinued operations is the cash received by a company that comes from the sale of part of business.

Ocumension Therapeutics's cash flow from discontinued operations for the six months ended in Dec. 2023 was HK$0.0 Mil. It means Ocumension Therapeutics received HK$0.0 Mil from the sale of part of business quarterly. Ocumension Therapeutics's cash flow from discontinued operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.0 Mil.

Ocumension Therapeutics Cash Flow from Discontinued Operations Historical Data

The historical data trend for Ocumension Therapeutics's Cash Flow from Discontinued Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ocumension Therapeutics Cash Flow from Discontinued Operations Chart

Ocumension Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Discontinued Operations
Get a 7-Day Free Trial - - - - -

Ocumension Therapeutics Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Discontinued Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Ocumension Therapeutics Cash Flow from Discontinued Operations Calculation

Cash received by a company that comes from the sale of part of business.

Cash Flow from Discontinued Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ocumension Therapeutics Cash Flow from Discontinued Operations Related Terms

Thank you for viewing the detailed overview of Ocumension Therapeutics's Cash Flow from Discontinued Operations provided by GuruFocus.com. Please click on the following links to see related term pages.

Ocumension Therapeutics (HKSE:01477) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ocumension Therapeutics (HKSE:01477) » Definitions » Cash Flow from Discontinued Operations
Comparable Companies
HKSE:02179 HKSE:02171 HKSE:02487 HKSE:02157 HKSE:02257 HKSE:00775 HKSE:01521 HKSE:02696 HKSE:02480 HKSE:06855 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
5DG:Germany
Address
No. 1858 Yinzhongnan Road, Guoxiang Subdistrict, Wuzhong District, Suzhou, Jiangsu, CHN
Website
http://www.ocumension.com
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Ocumension Therapeutics (HKSE:01477) Headlines

No Headlines